The National Institutes of Health (NIH) has announced a $21 million program to develop computer-based methods that model and simulate human hormone homeostasis. Named the Computational Modeling of Hormone Homeostasis Initiative, the award portfolio is intended to spur development of human data–driven computational models that reflect the self-regulating processes of hormones and their systemic effects. The program prioritizes producing models tailored to sex-specific physiology to support testing of therapeutics for effectiveness and toxicity.
NIH leaders stated that existing mathematical and animal models do not adequately capture biologic variation between men and women. Hormone activity differs widely between sexes and over an individual’s lifespan, producing variation in drug dosing requirements, treatment responses, and potential toxicity. The initiative frames this gap as a limitation to individualized therapeutics and to the accurate evaluation of new treatments when sex-specific biology is not adequately represented in preclinical or computational models.
Nicole Kleinstreuer, PhD, NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives, is quoted describing the goal of using advanced computer-based models built from human biological data to simulate hormone activity across the lifespan and improve evaluation of treatments and clinical decisions.
Funded projects under the initiative will develop computational techniques specifically designed to model and simulate sex-specific hormone homeostasis. The objective is to produce tools that allow researchers to test drugs and therapeutics in silico with models that represent male and female physiology and the dynamic regulation of hormones across different life stages.
Projects are expected to address both therapeutic effectiveness and toxicity, acknowledging that hormone-driven variation can influence both beneficial and adverse drug effects.
The initiative supports a range of computational approaches. Examples of awarded or promoted techniques include:
These methods are intended to capture dynamic, self-regulating hormone systems and their interactions with multiple organ systems.
A stated priority for the initiative is modeling hormone fluctuations and transitions over the life course. Examples cited include changes during puberty, the menstrual cycle, pregnancy, and menopause. NIH emphasizes that sex hormones interact with tissues beyond reproductive organs — including the lungs, bones, and the immune system — and that changes in hormone homeostasis can trigger systemic responses and long-term physiologic alterations.
Accounting for these life-course fluctuations and multi-organ interactions is presented as essential to produce clinically relevant models that can inform therapeutic development and individualized care.
NIH leaders framed the initiative as a means to improve preclinical testing and to support more informed clinical decision-making. By leveraging human-based computational models that explicitly incorporate sex as a biological variable (SABV) and lifespan dynamics, the program aims to streamline drug and biologics testing and to accelerate bench-to-bedside translation.
Janine Clayton, MD, FARVO, NIH Associate Director for Research on Women’s Health, commented that applying SABV principles to innovative modeling methods holds promise for amplifying impact and advancing understanding of the relationship between hormones and therapeutics.
The initiative’s funding is distributed through several award numbers: OD042764, OD042817, OD042825, OD042813, OD042820, and OD042823. The NIH has identified a program webpage for further information at the NIH hormone homeostasis site. The source article notes that more information can be found on that page.
The announcement reiterates NIH’s role as the nation’s medical research agency, responsible for conducting and supporting basic, clinical, and translational research across multiple diseases and conditions. The funding for this initiative is presented as consistent with NIH’s mission to investigate causes, treatments, and cures and to improve evaluation of new treatments by incorporating sex-specific biology into research infrastructure and computational tools.
In summary, NIH’s $21 million Computational Modeling of Hormone Homeostasis Initiative funds development of human-based, sex-specific computational models using a variety of advanced techniques. The program aims to address recognized shortcomings of current models, account for life-course hormonal dynamics and multi-organ effects, and ultimately improve assessment of therapeutic effectiveness and toxicity while supporting more individualized clinical decisions.